Aura Biosciences Statistics
Share Statistics
Aura Biosciences has 49.95M shares outstanding. The number of shares has increased by 0.7% in one year.
| Shares Outstanding | 49.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 42.92M |
| Failed to Deliver (FTD) Shares | 1.67K |
| FTD / Avg. Volume | 0.83% |
Short Selling Information
The latest short interest is 1.13M, so 2.28% of the outstanding shares have been sold short.
| Short Interest | 1.13M |
| Short % of Shares Out | 2.28% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 5.63 |
Valuation Ratios
The PE ratio is -4.59 and the forward PE ratio is -5.25.
| PE Ratio | -4.59 |
| Forward PE | -5.25 |
| PS Ratio | 0 |
| Forward PS | 22.5 |
| PB Ratio | 1.55 |
| P/FCF Ratio | -5.44 |
| PEG Ratio | n/a |
Enterprise Valuation
Aura Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 18.76, with a Debt / Equity ratio of 0.01.
| Current Ratio | 18.76 |
| Quick Ratio | 18.76 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.18 |
| Cash Flow / Debt | -23.76 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -34.7%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | -34.7% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -868.27K |
| Employee Count | 88 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 137.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -6.56% in the last 52 weeks. The beta is 0.33, so Aura Biosciences 's price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -6.56% |
| 50-Day Moving Average | 9.69 |
| 200-Day Moving Average | 8.42 |
| Relative Strength Index (RSI) | 38.65 |
| Average Volume (20 Days) | 201.11K |
Income Statement
In the last 12 months, Aura Biosciences had revenue of $0 and earned -$76.41M in profits. Earnings per share was $-1.93.
| Revenue | 0 |
| Gross Profit | -1.29M |
| Operating Income | -84.99M |
| Net Income | -76.41M |
| EBITDA | -83.70M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.93 |
Balance Sheet
The company has $41.06M in cash and $19.56M in debt, giving a net cash position of $21.51M.
| Cash & Cash Equivalents | 41.06M |
| Total Debt | 19.56M |
| Net Cash | 21.51M |
| Retained Earnings | -287.31M |
| Total Assets | 205.34M |
| Working Capital | 168.77M |
Cash Flow
In the last 12 months, operating cash flow was -$63.85M and capital expenditures -$709.00K, giving a free cash flow of -$64.56M.
| Operating Cash Flow | -63.85M |
| Capital Expenditures | -709.00K |
| Free Cash Flow | -64.56M |
| FCF Per Share | -1.63 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
AURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -22.95% |
| FCF Yield | -15.37% |
Analyst Forecast
The average price target for AURA is $23, which is 173.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 173.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 5.37 |
| Piotroski F-Score | 2 |